The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents

被引：15

作者：

Attal, Michel ^{[1
]}

Harousseau, Jean-Luc ^{[2
]}

机构：

[1] Ctr Hosp Purpan, F-31059 Toulouse, France

[2] CHU Nantes, Hotel Dieu, F-44035 Nantes 01, France

来源：

SEMINARS IN HEMATOLOGY | 2009年 / 46卷 / 02期

关键词：

DIAGNOSED MULTIPLE-MYELOMA; PLUS THALIDOMIDE; RANDOMIZED-TRIAL; STANDARD CHEMOTHERAPY; IMPROVES SURVIVAL; ELDERLY-PATIENTS; CLINICAL-TRIAL; TRANSPLANTATION; MELPHALAN; DEXAMETHASONE;

D O I：

10.1053/j.seminhematol.2009.02.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This review discusses the initial studies concerning the role of high-dose therapy (HDT) in multiple myeloma (MM) and gives the major conclusions drawn from this "historical period." Later, current studies using new drugs for HDT (induction, conditioning regimen, consolidation, and maintenance) are described and the promising results of this strategy reported. Finally, the issue of HDT in the era of new drug regimens is discussed, as well as the necessity of designing future trials comparing HDT and new drug regimens. Semin Hematol 46:127-132. (C) 2009 Published by Elsevier Inc.

引用

页码：127 / 132

页数：6

共 42 条

[1] RETRACTED: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma:: results of a multicenter randomized clinical trial (Retracted article. See vol. 113, pg. 6265, 2009) [J].

Abdelkefi, Abderrahman ;

Ladeb, Saloua ;

Torjman, Lamia ;

Ben Othman, Tarek ;

Lakhal, Amel ;

Ben Romdhane, Neila ;

El Omri, Halima ;

Elloumi, Moez ;

Belaaj, Hatem ;

Jeddi, Ramzi ;

Aissaoui, Lamia ;

Ksouri, Habib ;

Ben Hassen, Assia ;

Msadek, Fahmi ;

Saad, Ali ;

Hsaieri, Mohamed ;

Boukef, Kamel ;

Amouri, Ahlem ;

Louzir, Hechmi ;

Dellagi, Koussay ;

Ben Abdeladhim, Abdeladhim .

BLOOD, 2008, 111 (04) :1805-1810

[2] Single versus double autologous stem-cell transplantation for multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Facon, T ;

Guilhot, F ;

Doyen, C ;

Fuzibet, JG ;

Monconduit, M ;

Hulin, C ;

Caillot, D ;

Bouabdallah, R ;

Voillat, L ;

Sotto, JJ ;

Grosbois, B ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502

[3] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Stoppa, AM ;

Sotto, JJ ;

Fuzibet, JG ;

Rossi, JF ;

Casassus, P ;

Maisonneuve, H ;

Facon, T ;

Ifrah, N ;

Payen, C ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97

[4] Role of autologous stem-cell transplantation in multiple myeloma [J].

Attal, Michel ;

Harousseau, Jean-Luc .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (04) :747-759

[5] Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma [J].

Attal, Michel ;

Harousseau, Jean-Luc ;

Leyvraz, Serge ;

Doyen, Chantal ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Agha, Ibrahim Yakoub ;

Bourhis, Jean-Henri ;

Garderet, Laurent ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Renaud, Marc ;

Voillat, Laurent ;

Berthou, Christian ;

Marit, Gerald ;

Monconduit, Mathieu ;

Caillot, Denis ;

Grobois, Bernard ;

Avet-Loiseau, Herve ;

Moreau, Philippe ;

Facon, Thierry .

BLOOD, 2006, 108 (10) :3289-3294

[6] Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma [J].

Barlogie, B ;

Jagannath, S ;

Vesole, DH ;

Naucke, S ;

Cheson, B ;

Mattox, S ;

Bracy, D ;

Salmon, S ;

Jacobson, J ;

Crowley, J ;

Tricot, G .

BLOOD, 1997, 89 (03) :789-793

[7] Total therapy with tandem transplants for newly diagnosed multiple myeloma [J].

Barlogie, B ;

Jagannath, S ;

Desikan, KR ;

Mattox, S ;

Vesole, D ;

Siegel, D ;

Tricot, G ;

Munshi, N ;

Fassas, A ;

Singhal, S ;

Mehta, J ;

Anaissie, E ;

Dhodapkar, D ;

Naucke, S ;

Cromer, J ;

Sawyer, J ;

Epstein, J ;

Spoon, D ;

Ayers, D ;

Cheson, B ;

Crowley, J .

BLOOD, 1999, 93 (01) :55-65

[8] Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].

Barlogie, B ;

Tricot, G ;

Anaissie, E ;

Shaughnessy, J ;

Rasmussen, E ;

van Rhee, F ;

Fassas, A ;

Zangari, M ;

Hollmig, K ;

Pineda-Roman, M ;

Lee, C ;

Talamo, G ;

Thertulien, R ;

Kiwan, E ;

Krishna, S ;

Fox, M ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030

[9] Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321 [J].

Barlogie, B ;

Kyle, RA ;

Anderson, KC ;

Greipp, PR ;

Lazarus, HM ;

Hurd, DD ;

McCoy, J ;

Dakhil, SR ;

Lanier, KS ;

Chapman, RA ;

Cromer, JN ;

Salmon, SE ;

Durie, B ;

Crowley, JC .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :929-936

[10] Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities [J].

Barlogie, Bart ;

Pineda-Roman, Mauricio ;

Van Rhee, Frits ;

Haessler, Jeff ;

Anaissie, Elias ;

Hollmig, Klaus ;

Alsayed, Yazan ;

Waheed, Sarah ;

Petty, Nathan ;

Epstein, Joshua ;

Shaughnessy, John D., Jr. ;

Tricot, Guido ;

Zangari, Maurizio ;

Zeldis, Jerome ;

Barer, Sol ;

Crowley, John .

BLOOD, 2008, 112 (08) :3115-3121

← 1 2 3 4 5 →